Murat O. Arcasoy
Distinguished in Myeloproliferative Neoplasms (MPN)

Dr. Murat O. Arcasoy

Hematology Oncology | Hematology | Oncology
Duke University Medical Center, Box 3912 Dumc, 
Durham, NC 
Accepting New Patients
Distinguished in Myeloproliferative Neoplasms (MPN)
Duke University Medical Center, Box 3912 Dumc, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Murat Arcasoy is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Arcasoy is rated as a Distinguished provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Aspiration. Dr. Arcasoy is currently accepting new patients.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Myeloproliferative Neoplasms (MPN).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Piedmont
  • HMO
  • POS

Locations

Duke University Medical Center, Box 3912 Dumc, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
Enrollment Status: Terminated
Publish Date: November 15, 2022
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Enrollment Status: Completed
Publish Date: December 13, 2018
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Enrollment Status: Completed
Publish Date: January 11, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

34 Total Publications

Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.
Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.
Journal: Clinical advances in hematology & oncology : H&O
Published: March 06, 2024
Similar Doctors
Distinguished in Myeloproliferative Neoplasms (MPN)
Dr. Brandi N. Reeves
Hematology Oncology | Hematology | Oncology
Distinguished in Myeloproliferative Neoplasms (MPN)
Dr. Brandi N. Reeves
Hematology Oncology | Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.5 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brandi Reeves is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Reeves is rated as a Distinguished provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). Her top areas of expertise are Multiple Myeloma, Polycythemia Vera, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Reeves is currently accepting new patients.

Distinguished in Myeloproliferative Neoplasms (MPN)
Dr. Brendan D. Mcnulty
Hematology Oncology | Hematology | Oncology
Distinguished in Myeloproliferative Neoplasms (MPN)
Dr. Brendan D. Mcnulty
Hematology Oncology | Hematology | Oncology

Rex Hospital Inc

300 Health Park Dr, Suite 220, 
Garner, NC 
 (29.8 miles away)
919-250-5955
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brendan Mcnulty is a Hematologist Oncology specialist and a Hematologist in Garner, North Carolina. Dr. Mcnulty is rated as a Distinguished provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Anal Cancer, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Mcnulty is currently accepting new patients.

Robin L. Hardie
Advanced in Myeloproliferative Neoplasms (MPN)
Dr. Robin L. Hardie
Hematology Oncology | Hematology | Oncology
Advanced in Myeloproliferative Neoplasms (MPN)
Dr. Robin L. Hardie
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Experience:
27+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robin Hardie is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Hardie has been practicing medicine for over 27 years and is rated as a Distinguished provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). Her top areas of expertise are Paget Disease of the Breast, Monoclonal Gammopathy of Undetermined Significance (MGUS), Familial Colorectal Cancer, and Colorectal Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Arcasoy's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 9 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile